Year: 2019
Type: review
Abstract: Dilated cardiomyopathy (DCM) is characterized by left ventricular dilatation and, consecutively, contractile dysfunction. The causes of DCM are heterogeneous. DCM often results from myocarditis, exposure to alcohol, drugs or other toxins and metabolic or endocrine disturbances. In about 35% of patients, genetic mutations can be identified that usually involve genes responsible for cytoskeletal, sarcomere and nuclear envelope proteins. Due to its heterogeneity, a detailed diagnostic work-up is necessary to identify the specific underlying cause and exclude other conditions with phenotype overlap. Patients with DCM show typical systolic heart failure symptoms, but, with progress of the disease, diastolic dysfunction is present as well. Depending on the underlying pathology, DCM patients also become apparent through arrhythmias, thromboembolic events or cardiogenic shock. Disease progression and prognosis are mostly driven by disease severity and reverse remodelling within the heart. The worst prognosis is seen in patients with lowest ejection fractions or severe diastolic dysfunction, leading to terminal heart failure with subsequent need for left ventricular assist device implantation or heart transplantation. Guideline-based heart failure medication and device therapy reduces the frequency of heart failure hospitalizations and improves survival.
Source: Journal of Internal Medicine
DOI: 10.1111/joim.12944
Institution: Universität Hamburg
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: dilated cardiomyopathy, genetic mutations, sarcomere genes, nuclear envelope proteins, myocarditis, alcoholic cardiomyopathy, diastolic dysfunction, heart failure with reduced ejection fraction, cardiac arrhythmias, thromboembolism, cardiogenic shock, reverse remodeling, prognosis, heart failure medications, left ventricular assist device, heart transplantation
Open Access status: bronze
Award: G6367302337
OpenAlex ID: W2948006680
